Decreased heart rate recovery in patients with heart failure: Effect of fluvastatin therapy

International Heart Journal

Volumn 46, Issue 5, 2005, Pages 845-854

  Katircibasi, Mahmut Tuna ^a   Canatar, Taner ^a   Kocum, Halil Tolga ^a   Erol, Tansel ^a   Tekin, Goknur ^a   Demircan, Senol ^a   Tekin, Abdullah ^a   Sezgin, Alpay Turan ^a   Baltali, Mehmet ^a   Muderrisoglu, Haldun ^a  

^a BASKENT UNIVERSITY   (Turkey)

Author keywords

Fluvastatin; Heart failure; Heart rate recovery

Indexed keywords

ACETYLSALICYLIC ACID; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM ANTAGONIST; DIGOXIN; DIURETIC AGENT; FLUINDOSTATIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LESCOL XL; LIPID; LOW DENSITY LIPOPROTEIN CHOLESTEROL; TRIACYLGLYCEROL; HYPOCHOLESTEROLEMIC AGENT; INDOLE DERIVATIVE; MONOUNSATURATED FATTY ACID;

ADULT; AGED; ARTICLE; CHOLESTEROL BLOOD LEVEL; CLINICAL ARTICLE; CONTROLLED STUDY; CORONARY ARTERY DISEASE; CORRELATION ANALYSIS; FEMALE; FOLLOW UP; HEART FAILURE; HEART HEMODYNAMICS; HEART RATE; HUMAN; HYPERLIPIDEMIA; ISCHEMIC HEART DISEASE; LIPID ANALYSIS; MALE; PRIORITY JOURNAL; STATISTICAL SIGNIFICANCE; TIME; TRIACYLGLYCEROL BLOOD LEVEL; BLOOD; CHOLINERGIC SYSTEM; CONGESTIVE HEART FAILURE; CONVALESCENCE; CORONARY ARTERY ATHEROSCLEROSIS; EXERCISE; MIDDLE AGED; PATHOPHYSIOLOGY; PHYSIOLOGY;

AGED; ANTICHOLESTEREMIC AGENTS; CORONARY ARTERIOSCLEROSIS; EXERCISE; FATTY ACIDS, MONOUNSATURATED; FEMALE; HEART FAILURE, CONGESTIVE; HEART RATE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPERLIPIDEMIAS; INDOLES; LIPIDS; MALE; MIDDLE AGED; PARASYMPATHETIC NERVOUS SYSTEM; RECOVERY OF FUNCTION;

EID: 33644875464     PISSN: 13492365     EISSN: 13493299     Source Type: Journal    
DOI: 10.1536/ihj.46.845     Document Type: Article

References (50)

1. Arai Y, Saul JP, Albrecht P, et al. Modulation of cardiac autonomic activity during and immediately after exercise. Am J Physiol 1989; 256: H132-41.
2. Imai K, Sato H, Hori M, et al. Vagally mediated heart rate recovery after exercise is accelerated in athletes but blunted in patients with chronic heart failure. J Am Coll Cardiol 1994; 24: 1529-35.
3. Robinson S, Pearcy M, Brueckman FR, Nicholas JR, Miller DL. Effects of atropine on heart rate and oxygen intake in working man. J Appl Physiol 1953; 5: 508-12.
4. Pathak CL. Autoregulation of chronotropic response of the heart through pacemaker stretch. Cardiology 1973; 48: 45-64. (Review)
5. Savin WM, Davidson DM, Haskell WL. Autonomic contribution to heart rate recovery from exercise in humans. J Appl Physiol 1982; 53: 1572-5.
6. Cole CR, Blackstone EH, Pashkow FJ, Snader CE, Lauer MS. Heart-rate recovery immediately after exercise as a predictor of mortality. N Engl J Med 1999; 341: 1351-7.
7. Cole CR, Foody JM, Blackstone EH, Lauer MS. Heart rate recovery after submaximal exercise testing as a predictor of mortality in a cardiovascularly healthy cohort. Ann Intern Med 2000; 132: 552-5.
8. Lauer MS, Okin PM, Larson MG, Evans JC, Levy D. Impaired heart rate response to graded exercise. Prognostic implications of chronotropic incompetence in the Framingham Heart Study. Circulation 1996; 93: 1520-6.
9. Nishime EO, Cole CR, Blackstone EH, Pashkow FJ, Lauer MS. Heart rate recovery and treadmill exercise score as predictors of mortality in patients referred for exercise ECG. JAMA 2000; 284: 1392-8.
10. Sipahi I, Tekin G, Yigit Z, Guzelsoy D, Guven O. Effect of quinapril on the attenuated heart rate recovery of type 2 diabetic subjects without known coronary artery disease. Clin Cardiol 2004, 27; 480-4.
11. Racine N, Blanchet M, Ducharme A, et al. Decreased heart rate recovery after exercise in patients with congestive heart failure: Effect of β blocker therapy. J Card Fail 2003; 9: 296-302.
12. Horwich TB, MacLellan WR, Fonarow GC. Statin therapy is associated with improved survival in ishemic and non-ischemic heart failure. J Am Coll Cardiol 2004; 43: 642-8.
13. Laufs U, La Fata V, Plutzky J, Liao JK. Upregulation of endothelial nitric oxide synthase by HMG CoA reductase inhibitors. Circulation 1998; 97: 1129-35.
14. Kalinowski L, Dobrucki LW, Brovkovych V, Malinski T. Increased nitric oxide bioavailability in endothelial cells contributes to the pleiotropic effect of cerivastatin. Circulation 2002; 105: 933-8.
15. Wassmann S, Laufs U, Muller K, et al. Cellular antioxidant effects of atorvastatin in vitro and in vivo. Arterioscler Thromb Vasc Biol 2002; 22: 300-5.
16. Wagner AH, Kohler T, Ruckschloss U, Just I, Hecker M. Improvement of nitric oxide-dependent vasodilatation by HMG-CoA reductase inhibitors through attenuation of endothelial superoxide anion formation. Arterioscler Thromb Vasc Biol 2000; 20:61-9.
17. Pliquett RU, Cornish KG, Peuler JD, Zucker IH. Simvastatin normalizes autonomic neural control in experimental heart failure. Circulation 2003; 107: 2493-8.
18. Hernandez-Perera O, Perez-Sala D, Navarro-Antolin J, et al. Effects of the 3-hydroxy-3-methylglutaryl-CoA reductase inhibitors, atorvastatin and simvastatin, on the expression of endothelin-1 and endothelial nitric oxide synthase in vascular endothelial cells. J Clin Invest 1998; 101: 2711-9.
19. Nickenig G, Baumer AT, Temur Y, Kebben D, Jockenhovel F, Bohm M. Statin-sensitive dysregulated AT1 receptor function and density in hypercholesterolemic men. Circulation 1999; 100: 2131-4.
20. Alfon J, Guasch JF, Berrozpe M, Badimon L. Nitric oxide synthase II (NOS II) gene expression correlates with atherosclerotic intimal thickening. Preventive effects of HMG-CoA reductase inhibitors. Atherosclerosis 1999; 145: 325-31.
21. Liu JL, Pliquett RU, Brewer E, Cornish KG, Shen YT, Zucker IH. Chronic endothelin-1 blockade reduces sympathetic nerve activity in rabbits with heart failure. Am J Physiol Regul Integr Comp Physiol 2001; 280: R1906-13.
22. Kiowski W, Suetsch G, Oechslin E. Schalcher C, Brunner-Larocca HP, Bertel O. Rationale and perspective of endothelin-1 antagonism in acute heart failure. J Cardiovasc Pharmacol 2001; 38: S53-7.
23. Patel KP, Zhang K, Zucker IH, Krukoff TL. Decreased gene expression of neuronal nitric oxide synthase in hypothalamus and brainstem of rats in heart failure. Brain Res 1996; 734: 109-15.
24. AdLer S, Huang H, Loke K, Xu X, Laumas A, Hintze TH. Modulation of renal oxygen consumption by nitric oxide is impaired after development of congestive heart failure in dogs. J Cardiovasc Pharmacol 2001; 37: 301-9.
25. Dzau VJ, Colucci WS, Hollenberg NK, Williams GH. Relation of renin-angiotensin-aldosterone system to clinical state of congestive heart failure. Circulation 1981; 63: 645-51.
26. Brooks VL. Interactions between angiotensin II and the sympathetic nervous system in the long-term control of arterial pressure. Clin Exp Pharmacol Physiol 1997; 24: 83-90. (Review)
27. Bains JS, Ferguson AV. Angiotensin II neurotransmitter actions in paraventricular nucleus are potentiated by a nitric oxide synthase inhibitor. Regul Pept 1994; 50: 53-9.
28. Bigi R, Verzoni A, Cortigiani L, De Chiara B, Desideri A, Fiorentini C. Effect of pharmacological wash-out in patients undergoing exercise testing after acute myocardial infarction. Int J Cardiol 2004; 97: 277-81.
29. Diaz LA, Brunken RC, Blackstone EH, Snader CE, Lauer MS. Independent contribution of myocardial perfusion defects to exercise capacity and heart rate recovery for prediction of all-cause mortality in patients with known or suspected coronary heart disease. J Am Coll Cardiol 2001; 37: 1558-64.
30. Yasumura Y, Kohno H, Shimizu H, et al. Usefulness of low doses of atropine to quantify the vagal stimulus-response relation in patients with congestive heart failure. Am J Cardiol 1997; 80: 1459-63.
31. Cohn JN, Levine TB, Olivari MT, et al. Plasma norepinephrine as a guide to prognosis in patients with chronic congestive heart failure. N Engl J Med 1984; 311: 819-23.
32. Kaye DM, Letkovits J, Jennings GL, Bergin P, Broughton A, Esler MD. Adverse consequences of high sympathetic nervous activity in the failing human heart. J Am Coll Cardiol 1995; 26: 1257-63.
33. Francis GS, Goldsmith SR, Levine TB, Olivari MT, Cohn JN. The neurohumoral axis in congestive heart failure. Ann Intern Med 1984; 101: 370-7. (Review)
34. Krum H, Goldsmith R, Wilshire-Clement M, Miller M, Packer M. Role of endothelin in the exercise intolerance of chronic heart failure. Am J Cardiol 1995; 75: 1282-3.
35. Huang PH, Leu HB, Chen JW, et al. Usefulness of attenuated heart rate recovery immediately after exercise to predict endothelial dysfunction in patients with suspected coronary artery disease. Am J Cardiol 2004; 93: 10-3.
36. O'Driscoll G, Green D, Taylor RR. Simvastatin, an HMG co-enzyme. A reductase inhibitor, improves endothelial function within 1 month. Circulation 1997; 95: 1126-31.
37. Treasure CB, Klein JL, Weintraub WS, et al. Beneficial effects of cholesterol-lowering therapy on the coronary endothelium in patients with coronary artery disease. N Engl J Med 1995; 332: 481-7.
38. Dupuis J. Mechanisms of acute coronary syndromes and the potential role of statins. Atheroscler Suppl 2001; 2: 9-14. (Review)
39. Baller D, Notohamiprodjo G, Gleichmann U, Holzinger J, Weise R, Lehmann J. Improvement in coronary flow reserve determined by positron emission tomography after 6 months of cholesterol-lowering therapy in patients with early stages of coronary atherosclerosis. Circulation 1999; 99: 2871-5.
40. Seljeflot I, Tonstad S, Hjermann I, Arnesen H. Reduced expression of endothelial cell markers after 1 year treatment with simvastatin and atorvastatin in patients with coronary heart disease. Atherosclerosis 2002; 162: 179-85.
41. The Scandinavian Simvastatin Survival Study Group. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: The Scandinavian Simvastatin Survival Study (4S). Lancet 1994; 344: 1383-9.
42. The Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. N Engl J Med 1998; 339: 1349-57.
43. Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: A randomised placebo-controlled trial. Lancet 2002; 360: 7-22.
44. Sacks FM, Pfeffer MA, Moye LA, et al. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators. N Engl J Med 1996; 335: 1001-9.
45. Mozaffarian D, Nye R, Levy WC. Statin therapy is associated with lower mortality among patients with severe heart failure. Am J Cardiol 2004; 93: 1124-9.
46. Pliquett RU, Cornish KG, Zudker IH. Statin therapy restores sympathovagal balance in experimental heart failure. J Appl Physiol 2003; 95: 700-4.
47. Patterson D, Dick JB, Struthers AD. Intensive statin treatment improves baroreflex sensitivity: Another cardio-protective mechanism for statins? Heart 2002; 88: 415-6.
48. Hamelin BA, Turgeon J. Hydrophilicity/lipophilicity: Relevance for the pharmacology and clinical effects of HMG-CoA reductase inhibitors. Trends Pharmacol Sci 1998; 19: 26-37. (Review)
49. Bocan TM, Ferguson E, McNally W, et al. Hepatic and nonhepatic sterol synthesis and tissue distribution following administration of a liver selective HMG-CoA reductase inhibitor, CI 981: Comparison with selected HMG-CoA reductase inhibitors. Biochim Biophys Acta 1992; 1123: 133-44.
50. Haigh LS, Leatherman GF, O'Hara DS, Smith TW, Galper JB. Effects of low density lipoproteins and mevinolin on cholesterol content and muscarinic cholinergic responsiveness in cultured chick atrial cells. Regulation of levels of muscarinic receptors and guanine nucleotide regulatory proteins. J Biol Chem 1988; 263: 15608-18.